{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0311","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.96","upperLimit":"8.54","value":"6.83"},{"groupId":"OG001","lowerLimit":"4.24","upperLimit":"5.72","value":"4.93"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"249"}],"units":"Participants"}],"description":"Progression Free Survival defined as the duration in months from randomization until first evidence of confirmed disease progression, as assessed by the Independent Review Committee (IRC) according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). Disease progression was defined according to the IMWG-URC as progressive disease or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Melflufen 40 mg i.v. on Day 1 and dexamethasone 40 mg (20 mg for patients ≥ 75 years of age) on Days 1, 8, 15 and 22 of each 28-day cycle. Patients were to be treated until confirmed progression, unacceptable toxicity, or the patient or investigator decided it was not in the patient's best interest to continue.\n\nMelflufen: Intravenous infusion\n\nDexamethasone: Oral tablets","id":"OG000","title":"Arm A: Melflufen+Dexamethasone"},{"description":"Pomalidomide 4 mg orally daily on Days 1 to 21 and dexamethasone 40 mg (20 mg for patients ≥ 75 years of age) on Days 1, 8, 15 and 22 of each 28-day cycle. Patients were to be treated until confirmed progression, unacceptable toxicity, or the patient or investigator decided it was not in the patient's best interest to continue.\n\nPomalidomide: Oral capsules\n\nDexamethasone: Oral tablets","id":"OG001","title":"Arm B: Pomalidomide+Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"All randomized patients (Full Analysis Set as per protocol) were included into the primary outcome measure analysis.","reportingStatus":"POSTED","timeFrame":"From date of randomization until first evidence of confirmed disease progression or death due to any cause (whichever occurred first), up to the data cutoff date of 03 Feb 2021 (ie, assessed up to approximately 43 months).","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}